Clinical Research Directory

Inclusion Criteria: * Histologically confirmed non-mucinous colon adenocarcinoma. * Primary tumor as pT1-3, pN0 or pN1 (metastases in \< 4 regional lymph nodes), confirmed R0 resection. * RAS and BRAF wild-type \& MSS molecular status as per local testing. * Liver metastases not eligible for curative liver resection * Objective response according to RECIST 1.1 to first-line treatment, with sustained response for at least 4 months, OR disease control (CR+PR+SD) during second-line treatment for at least 4 months. * A maximum of two prior chemotherapy treatment lines. * Performance status, ECOG 0. * Satisfactory blood tests Hb \>10g/dl, neutrophils \>1.0 (after any G-CSF), TRC \>75, Bilirubin\<2 x upper normal level, AST, ALT\<5 x upper normal level, creatinine \<1.25 x upper normal level. * CEA\<50 ng/ml Exclusion Criteria: * Hereditary CRC syndromes including FAP and Lynch syndrome. * Prior extra hepatic metastatic disease or primary tumor local relapse. * Extra-peritoneal cancers (rectum). * Other malignancies in the previous 5 years * Active intra-venous or alcohol abusers * HIV infection